FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Ideogen Pharma to exclusively distribute Bicnu® (Emcure) via a Managed Access Program for targeted Healthcare Providers in Switzerland.
BiCNU® (Carmustine for injection) is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in Brain tumors – (glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors), Multiple myeloma, Hodgkin’s disease and Non-Hodgkin’s lymphomas.
Program Contact details
For all inquiries regarding Bicnu®, please contact FarmaMondo Program Manager, Bicnu®, Swiss Access. email@example.com, Phone: +41 91 6976390
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
About Ideogen Pharma
Ideogen pharma is a specialty-care focused pharmaceutical group with the ability offer healthcare providers access to unique treatment options in Oncology, Hematology, Infectious Disease, Nephrology and Rare-Diseases. Ideogen is the marketing rights holder for Bicnu® Carmustine for injection for the Swiss market.